Introduction
Over recent decades, the number of people with immune system disorders has increased markedly. Such individuals include those who are diabetic, patients with haematological malignancies such as acute leukaemia, cancer patients who are exposed to high doses of chemotherapy or radiation therapy, transplantation surgery patients and HIV-positive individuals [1] . According to the World Health Organisation, the number of HIV infected humans in 2008 reached 33.4 million [2] . In the same year, the number of cancer cases amounted to 20 million [3] , whilst latest data show that 347 million people suffer Abstract Opportunistic oral infections caused by Candida albicans are frequent problems in immunocompromised patients. Management of such infections is limited due to the low number of antifungal drugs available, their relatively high toxicity and the emergence of antifungal resistance. Given these issues, our investigations have focused on novel derivatives of the antifungal antibiotic Nystatin A 1 , generated by modifications at the amino group of this molecule. The aims of this study were to evaluate the antifungal effectiveness and host cell toxicity of these new compounds using an in vitro model of oral candidosis based on a reconstituted human oral epithelium (RHOE). Initial studies employing broth microdilution, revealed that against planktonic C. albicans, Nystatin A 1 from diabetes mellitus [4] . Associated with the chronic problems of the immunocompromised are the occurrence of opportunistic infections such as oral candidoses (OC) [5] [6] [7] .
The principal causative agent of oral candidosis is Candida albicans. This polymorphic fungus is frequently present in humans as a harmless commensal, and when individuals become debilitated, C. albicans overgrowth may occur leading to infection [8, 9] .
Currently, azoles and polyenes are the two main classes of antifungal drugs used to treat oral candidosis [10] [11] [12] . Azoles inhibit the fungal cytochrome P450 (CYP)-dependent enzyme, lanosterol 14 α-demethylase, involved in ergosterol biosynthesis. Ergosterol depletion and accumulation of improper sterols result, thereby impairing structure and function of the fungal cell membrane [11] [12] [13] .
However, through inhibition of the human cytochrome P450 (CYP) enzyme system, azoles can initiate undesirable drug-drug interactions reducing drug absorption and increasing the risk of adverse effects [13] . The emergence of Candida resistance to azoles is also of increasing concern [14] .
Polyene antibiotics (e.g. Nystatin and Amphotericin B) bind directly to ergosterol forming transmembrane channels, which significantly increase membrane permeability and cause leakage of cellular contents. High fungicidal action and low incidence of fungal resistance are key benefits of polyenes. However, despite greater affinity to the fungal sterol, ergosterol, there is a tendency for polyenes to also interact with the human membrane component, cholesterol, and this can lead to side effects [15] . Furthermore, low absorption through the gastrointestinal tract creates difficulties for drug administration and limits polyenes to topical application in oral candidosis [10, 15] .
Given current antifungal limitations and the ensuing frequent recurrence of Candida infections [16] , there is urgent need for the development of novel and advanced antifungal agents. One proposed strategy is rational chemical modification, designed to improve existing properties of native drugs [17] [18] [19] .
Prior to this present study, modifications to the structure of Nystatin A 1 ( Fig. 1 ) to reduce its toxicity and increase its water solubility were undertaken. Previous reports have shown that an amino group of the polyene molecule plays an essential role in membrane interactions, whilst the presence of additional polar functional groups may improve water solubility [17, 19, 20] . Therefore, novel N-substituted derivatives of Nystatin A 1 have been recently synthesised as potential antifungal agents [21] .
The aims of this investigation were to assess both the anti-candidal properties and also host cell toxicity of these novel Nystatin A 1 derivatives. Antifungal activity against C. albicans and cytotoxic effects on a human keratinocyte cell line were initially examined. Subsequently, the performance of selected derivatives against Candida infection of a reconstituted human oral epithelium (RHOE) was examined. In these studies, the extent of epithelial cell damage/ viability was measured using lactate dehydrogenase activity and live/dead staining. The degree of tissue colonisation and profile of tissue invasion by C. albicans were assessed using immunofluorescence labelling and confocal laser scanning microscopy (CLSM). Candida viability was also determined by live/dead staining and CLSM imaging. 
Materials and methods

Candida albicans and reconstituted human oral epithelium
All experiments were performed using the reference strain of C. albicans ATCC 10231. Cytotoxic effects of antifungal drugs were initially tested using a human keratinocyte cell line (HaCaT) from the collection of the School of Dentistry, Cardiff University (UK). A commercially available reconstituted human oral epithelium (RHOE, SkinEthic Laboratories; Nice, France) that had previously been established as an in vitro tissue model of oral candidosis [22, 23] was utilised in infection studies.
Antifungal compounds
Nystatin A 1 (Nys) was obtained from Sigma-Aldrich (Poole, UK), and the novel Nystatin A 1 derivatives were designed and synthesised at BLIRT S.A. Company, Gdańsk (Poland) [21] and the Department of Organic Chemistry and Department of Pharmaceutical Technology and Biochemistry at GUT (Poland). All derivatives were divided into defined classes based on the functional group attached to the nitrogen atom in the native macrolide structure, and selected representatives (Nys1, Nys2, Nys4, Nys5, Nys6, Nys7 and Nys8) were the focus of these studies. These derivatives all formed water-soluble salts. N-fructosyl Nystatin A 1 (Nys3) [24] was used as a reference derivative of Nystatin A 1 . Stock solutions of Nystatin A 1 and the derivatives were prepared in dimethyl sulfoxide (DMSO; SigmaAldrich). As the native Nystatin A 1 is water-insoluble and requires the use of DMSO to make the stock solution, the antibiotic derivatives were not used in the form of their water-soluble salts, to ensure the same conditions for testing of all compounds.
Antifungal susceptibility testing
In vitro antifungal activity of Nystatin A 1 and N-substituted derivatives was initially measured based on the broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS), [25] with the exception that a final inoculum density of 1 × 10 4 cells ml
was used. The minimal inhibitory concentration (MIC) was determined for C. albicans using RPMI-1640 medium (with l-glutamine and phenol red, without sodium bicarbonate, Sigma-Aldrich, Poole, UK) buffered to pH 7.0 with MOPS buffer ([3-(N-morpholino) propanesulfonic acid], Sigma-Aldrich). Appropriate compounds previously prepared in DMSO were diluted in the RPMI-1640 medium to give final concentration ranges of 0.03125-16 µg ml −1 for Nystatin A 1 and 0.250-128 µg ml −1 for the new derivatives. The final DMSO concentration in each test well was 1 % (v/v). Microtitre plates were incubated at 37 °C , and optical absorbance (OD531 nm ) recorded after 24 h with a plate reader (VICTOR 3 ™ Multilabel Counter, Perkin Elmer, Massachusetts, USA). The MIC was defined as the lowest compound concentration that provided complete inhibition of visible growth. Half maximal inhibitory concentrations (IC50-C) were also estimated by preparing graphs from measured optical densities (OD531 nm ) as a function of drug concentration and fitting these data to the sigmoidal doseresponse equations using Origin Pro 8.1 software (OriginLab Corporation, Northampton, USA). Susceptibility tests were repeated on three separate occasions.
Cytotoxicity studies of antifungal compounds
The in vitro cytotoxic effects of Nystatin A 1 and the novel derivatives on human cells were determined using a keratinocyte cell line (HaCaT) in DMEM medium containing high glucose concentration and l-glutamine (Lonza Group Ltd., Basel, Switzerland) supplemented with 10 % foetal bovine serum (FBS) and penicillin/streptomycin (100 U ml −1 and 100 µg ml
, respectively; Lonza Group Ltd.). After washing twice with phosphate-buffered saline (PBS, pH = 7.0), HaCaT cells were harvested using trypsin-EDTA solution (Lonza Group Ltd.) and the number of cells enumerated with a haemocytometer before adjustment to a density of 2 × 10 6 cells ml −1 in DMEM. Serial doubling dilutions of the keratinocyte cell suspension were performed in a 96-well tissue culture plate (Sarstedt, Nüm-brecht, Germany), which also included a growth control commencing at 1 × 10 5 cells ml −1 . For drug testing, 100 µl of 2 × 10 4 cells were seeded in each well with the same volume of appropriately diluted compound in culture medium. The antifungal concentration range was 12.5-300 µg ml −1 , and the final DMSO concentration in all microtitre wells was 1 % (v/v). Keratinocytes were incubated for 3 days at 37 °C in a humidified atmosphere containing 5 % CO 2 . After incubation, cell viability was determined using Cell Counting Kit-8 (CCK-8; Sigma-Aldrich). This colorimetric assay was based on the reduction of water-soluble tetrazolium salt to a coloured formazan product by active dehydrogenases of viable cells. The amount of water-soluble formazan dye was therefore directly proportional to the number of living cells. After 3 days, 100 µl of the removed culture medium was replaced by 100 µl of tenfold diluted CCK-8 reagent. Incubation continued for another 4 h, and the absorbance was then measured at 450 nm in a plate reader (FLUOstar Omega; BMG LABTECH GmbH, Ortenberg, Germany). Cell viability was evaluated by plotting optical density values (OD 450 ) as a function of drug concentration, and the IC50-H (half maximal inhibitory concentration) value calculated by fitting the results to the sigmoidal dose-response equations in the Origin Pro 8.1 software. For each compound, the experiments were performed in triplicate.
In vitro tissue model of oral candidosis treated with antifungals
To further examine antifungal effectiveness of the compounds, an in vitro tissue model of oral candidosis was utilised. In these studies, a RHOE infected with C. albicans was used. Before each experiment, C. albicans was cultured on Sabouraud Dextrose Agar (Oxoid Ltd., Hampshire, UK) for 48 h at 37 °C , and a portion of colony resuspended and incubated in Yeast Nitrogen Base medium (0.67 % YNB without amino acids; BD Diagnostics, Cowley, UK) supplemented with 0.5 % (w/v) glucose (Merck, Darmstadt, Germany) for 12 h with gentle agitation at 37 °C . Cells were harvested by centrifugation and then washed three times with sterile phosphate-buffered saline (PBS, pH = 7.0) before resuspension in fresh PBS.
To establish in vitro tissue infection, Candida yeast was enumerated in an improved Neubauer haemocytometer and adjusted to a final concentration of 2 × 10 6 cells ml −1 in the Maintenance Medium (SkinEthic Laboratories, Nice, France) used for RHOE cultivation. Finally, RHOE tissue inserts (0.5 cm 2 , age day 5) were transferred to a sterile 24-well tissue culture plate (Sarstedt, Nümbrecht, Germany) and inoculated with 1 ml of standardised yeast suspension (2 × 10 6 cells ml −1 ). A control of non-infected tissue with 1 ml of medium devoid of Candida was also prepared. All tissues were incubated for 6 h at 37 °C in a humidified atmosphere with 5 % CO 2 . Supernatants were then removed, and 1 ml of the test antifungal compound solution in Maintenance Medium was added to the tissue surfaces. Experiments were performed at a total drug concentration of 150 µg ml −1 in 1 % (v/v) DMSO. Maximal fungal infection controls were obtained by incubation of RHOE tissue with Maintenance Medium incorporating 1 % (v/v) DMSO. Non-infected tissue controls used fresh medium containing 1 % (v/v) DMSO in place of supernatant. After overnight incubation, supernatant was collected for lactate dehydrogenase measurement and the tissues were rinsed with PBS. All inserts were divided in half, with one portion used for live/dead staining and the other portion prepared for CLSM. All experiments were performed on five separate occasions.
Live/dead assay of infected tissues Determination of C. albicans viability after antifungal treatment was based on the use of live/dead staining. Portions of fresh (i.e. not fixed) RHOE tissues post-infection were placed on microscope slides, and 100 µl of a fluorescent dye mixture (25 µM Syto9 and 15 µM propidium iodide; Molecular Probes-Invitrogen, Paisley, UK) added. The green fluorescing nucleic acid dye, Syto9, was used to stain live and dead cells, whilst the red fluorescing dye, propidium iodide, stained only dead cells. Samples were incubated for 30 min at 37 °C in the dark, transferred to clean slides and overlaid with Vectashield mounting medium (H-1000, Vector Laboratories, Inc., Burlingame, CA) for prevention of dye photo bleaching. Stained tissues were observed by CLSM using a Leica TCS SP2 AOBS spectral confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany). Tissue halves were scanned through a 15-µm depth with a ×40 objective lens at a Z-step of approximately 0.5 µm. To eliminate spectral bleed-through between fluorescent probes, sections were scanned using appropriate settings for sequential fluorescence recordings of Syto9 (ex/em max: 480/500 nm ) and propidium iodide (ex/em max: 490/635 nm ). Images were presented as maximum intensity type reconstructions and were used for fluorescent areas enumerations. The experiments were performed in triplicate.
Live/dead cell determination
The effect of the tested compounds on both C. albicans and RHOE cell viability was determined from confocal microscopy images. Total area of green and red fluorescence in relation to each image area was calculated using an image analysis program-ImageJ 1.46r (Wayne Rasband, National Institute of Health, USA).
Briefly, the single image was separated into its constituent green and red channels (Image/Colour/Split Channels), and after the first channel was chosen, the function of threshold intensity was utilised (Image/Adjust/Threshold) according to pixel intensity to generate a binary image. The total area occupied by both epithelial and fungal cells was quantified using an 'analyse particles' tool (Analyse/ Analyse Particles). Next, the epithelial cells were marked with a freehand selections tool, and their area measured with the 'analyse particles' command. Given the larger size and more regular shape of the epithelial cells compared with fungal elements, differentiation of the former by the software was readily achievable. The area of the epithelial cells was then subtracted from the total area employed by both Candida and epithelial cells, and using this approach, an area of fungal cells was calculated (both hyphae and yeast forms). A similar pathway was applied for the second channel. Finally, the percentage of green and red fluorescence of epithelial cells was calculated by dividing the fluorescence area from one channel by the sum of fluorescence areas for both channels. The same method was used to calculate the fluorescence of Candida albicans cells. Results were presented as a mean of three independent images.
Tissue sections preparation for CLSM Tissue colonisation and invasion by C. albicans in the presence and absence of antifungal agents was determined by CLSM after immunofluorescent labelling of tissue sections. After incubation, tissues were fixed in formalin for 24 h at 4 °C and embedded in paraffin wax. Tissues sections (20 µm) were placed on Histobond + coated microscope slides (Raymond A Lamb, East Sussex, UK), de-waxed, re-hydrated and heated twice for 5 min at 95 °C in 10 mM citrate buffer (pH = 6.0) to break formalin cross-links and expose target antigens. After cooling, sections were washed in water (×3 for 2 min), and potential non-specific binding sites blocked with normal goat serum (Sigma-Aldrich) at a 1:20 dilution for 30 min at room temperature. Subsequently, sections were incubated overnight at 4 °C with a mouse monoclonal IgG pan-cytokeratin primary antibody at 2 µg ml −1 (Santa Cruz Biotechnology, Inc., Dallas, USA). Tissue sections were then washed (×2 for 5 min) in PBS and labelled with Alexa Fluor 488 goat anti-mouse IgG secondary antibody (5 µg ml Stained sections were washed, mounted with Vectashield mounting and analysed by CLSM using a Leica TCS SP2 AOBS spectral confocal microscope (Leica Microsystems GmbH). Sections were scanned sequentially through their depth using appropriate scan settings for sequential fluorescence recording of Alexa 488 (ex/em max: 495/519 nm ), Alexa 594 (ex/em max: 590/617 nm ) and Hoechst 33258 (ex/ em max: 352/461 nm ) with a ×40 objective lens at a Z-step of approximately 0.5 µm. Images were presented as maximum intensity reconstructions. Candida albicans were represented by red Alexa 594 fluorescence, keratinocytes by green Alexa 488 fluorescence and cell nuclei by blue Hoechst 33258 fluorescence. The experiments were performed in five replicates.
For precise determination of the effect of tested compounds on the epithelial colonisation by Candida, the thickness of fungal layers on RHOE sections was measured by CLSM. Calculations were made with the ImageJ 1.46r program by dividing the area surface by the width of the Candida layer. Results were presented diagrammatically as a mean of three separate images.
Measurement of lactate dehydrogenase activity
The extracellular activity of lactate dehydrogenase (LDH) released from epithelial cells was monitored as an indicator of tissue cell damage. Enzyme activity was measured from collected culture medium after infection of RHOE tissues with C. albicans and treatment with antifungal drugs dissolved in DMSO, or RHOE in the presence 1 % (v/v) DMSO without antifungal. To investigate the effect of compounds on epithelial cells in the absence of Candida, controls of uninfected tissues as well as those incubated with 1 % (v/v) DMSO or with just 150 µg ml −1 of antifungals were also tested. For determination of LDH activity, a CytoTox-ONE Homogeneous Integrity Assay (Promega, Madison, USA) was used. The method was based on the formation of a fluorescent product as a result of the coenzyme NADH diminishing during the LDH catalysed reaction. The intensity of fluorescence was analysed with a plate reader (FLUOstar Optima) at appropriate excitation 544 nm and emission 590 nm wavelengths, and was proportional to the number of damaged cells. The LDH activity of culture medium alone was subtracted from LDH activity of tissue samples and results expressed as a cytotoxicity percentage relative to the maximum enzyme release (LDH activity from Candida infected, untreated controls). The experiments were performed in five replicates for infected tissues and in duplicate for non-infected ones.
Statistical analysis
Statistical analysis of data was performed using Origin Pro 8.1 software (OriginLab Corporation, Northampton, USA). Data were presented as an arithmetic mean ± SD. The results of fluorescent area calculations, LDH release measurements as well as Candida biofilm thickness and HaCaT cell viability after treatment with Nystatin A 1 and the novel derivatives were compared using a one-way analysis of variance (ANOVA) by applying a Tukey multiple comparisons test. Statistically significant differences were set at P < 0.05.
Results
In vitro antifungal and cytotoxic effect of Nystatin A 1 and novel derivatives The in vitro antifungal susceptibility studies showed that all examined derivatives were active against C. albicans ATCC 10231. However, the derivatives exhibited slightly higher MIC values compared with the native drug ( Table 1) .
Amongst the tested derivatives, good antifungal activity (MIC of 2 µg ml ) occurred with Nys5, and MICs of 4 µg ml −1 were evident with Nys1, Nys2, Nys7 and Nys8. The similar antifungal effect of these derivatives against C. albicans seemed to be independent of the functional group present. According to IC50-C calculations, Nys5 was selected (1.19 µg ml ) as the most potent antifungal Nystatin A 1 derivative. It was also interesting that Nys1 and Nys7, although representing different types of modifications, were characterised by identical antifungal activity, with both giving the same MIC and IC50-C (2.81 µg ml ) values. To determine cytotoxic effects of Nystatin A 1 and its derivatives, a keratinocyte cell line (HaCaT) representing the major cell type within a multilayered human epithelium was used. The results revealed that the substitution of the amino group in the Nystatin A 1 molecule resulted in reduced toxicity of new polyene compounds ( Table 2 ). The semisynthetic derivatives had no significant effect on the vitality of human keratinocytes up to 300 µg ml −1 . In contrast, the native Nystatin A 1 displayed high keratinocyte cytotoxicity with an IC50-H value of 50.82 µg ml −1 . For further investigations, Nys5 was selected due to it having the lowest IC50 value found in the antifungal activity determination, and two other derivatives (Nys1 and Nys7) were also selected as representatives of different structural groups.
Viability of Candida albicans and epithelial cells in the RHOE model of fungal infection
To examine whether novel derivatives had the ability to kill C. albicans during in vitro RHOE infection and to assess the influence of these agents on epithelial cell viability, an in vitro infection model was used.
All infected tissues (Fig. 2b-f) were colonised by C. albicans. To compare CLSM images, the relative percentage of green and red fluorescent areas was calculated, and the overall ratio of live and dead cells determined. Compared with the control treated with only 1 % (v/v) DMSO, where 99 % of Candida cells were live (green; Fig. 2b ), both the natural Nystatin A 1 and selected derivatives, namely Nys1, Nys5 and Nys7 resulted in red staining of C. albicans, typically depicting cell death. The new Nystatin A 1 derivatives were more effective against Candida in the tissue infection compared with the native drug alone (P < 0.05).
The most active compound, Nys7, generated an 88.5 % area of red fluorescing Candida, whilst treatment with Nystatin A 1 resulted in only a 35 % area of dead Candida (Fig. 3a) . Incubation with derivative Nys5 resulted in a 77 % area of dead Candida compared with a 69 % dead area with Nys1.
The viability of tissue keratinocytes was also calculated (Fig. 3b) . In the drug-free control (infected with C. albicans), 99 % of Candida infected epithelial cells exhibited red fluorescence. Treatment with native Nystatin A 1 resulted in a statistical reduction in the epithelial cell death compared with this control (P < 0.05). However, high levels of red epithelial cell fluorescence amounting to 78 % remained evident. Interestingly, treatment using the novel compounds resulted in significantly lower areas of red (i.e. dead) epithelial cells than the parent drug. It was established that both Nys1 and Nys5 derivatives had no impact on human keratinocyte viability in the in vitro model compared with the uninfected tissue control (P > 0.05) with almost 90 % of these cells remaining green (i.e. viable) after treatment. Only Nys7 demonstrated some toxic effect, since a 48 % area of epithelial cells was deemed to be red.
In conclusion, tested Nystatin A 1 derivatives caused high levels of Candida cell death and also demonstrated low toxicity to human oral epithelium. 
N-alkyl derivatives
Nys1 >300
N-aminoacyl derivatives
Nys2 >300
N-fructosyl derivatives
Nys3 >300
N-succinimidyl derivatives
Nys4 >300
Nys5 >300
Thioureidyl derivatives
Nys6 >300 Nys7 >300 Nys8 >300 
Novel antifungal compounds in inhibiting colonisation and invasion of oral epithelium by C. albicans
From these studies, the aim was to measure changes in the progress of fungal infection and assess whether differences occurred due to the presence of new antifungal compounds. Experiments revealed a high ability of C. albicans ATCC 10231 to colonise the surface of the human oral epithelium in the drug-free control. There was a high tendency for C. albicans to generate a biofilm-like structure, where most of the fungal cells were in the form of hyphae. In the absence of antifungals, the RHOE was completely invaded by the fungal elements, with both hyphae (predominantly) and some yeast forms detected even at the base of the epithelium. This resulted in the separation of keratinocytes from the membrane insert base and detachment of the epithelium (Fig. 4) . Compared with uninfected controls, areas of vacuolation in the tissue structure could also be seen as further evidence of tissue damage.
The action of antifungal compounds significantly inhibited the progress of RHOE infection (Fig. 5) . After treatment with native Nystatin A 1 , Candida still colonised the surface of the epithelium, but penetration into the tissue was not observed. The fungal layer was twofold thinner than in the control of solvent alone (1 % (v/v) DMSO; 100.1 µm biofilm thickness; Fig. 6) ; however, Candida hyphae remained tightly clustered (Fig. 5b) .
Treatment with compound Nys1 did not entirely prevent C. albicans invasion of the RHOE (Table 3) , although only the upper layers of the epithelium were invaded. Within the tissue, the presence of both hyphae and yeast was observed (Fig. 5c) . It was also evident that fungal cells were not organised within a typical biofilmlike form, as noted with the Nystatin A 1 and two other derivatives. In contrast, the stratified growth of Candida appeared to be retarded, and this resulted in the greatest decrease in the area (24.7 µm thick) occupied by the fungal cells on the epithelial surface, compared with all the tested compounds (Fig. 6) .
In the case of the Nys5 derivative-treated oral epithelium, a thin (~35 µm) Candida biofilm was detected. However, the Candida did not invade the oral epithelium, implying a similar effect of this novel Nystatin derivative to the native drug. Furthermore, fungal colonisation of the RHOE was less extensive compared with the Nystatin A 1 -treated tissue, where the Candida layer measured 49.4 µm and the structure of the biofilm was less densely organised (Fig. 5d) .
After treatment with Nys7, the RHOE was covered by a thin (31.6 µm) and poorly compacted layer of fungal cells, predominantly in hyphal form, similar to that seen in the tissue treated with Nys5. A few Candida invaded through the epithelium (Fig. 5e ), but at a noticeably reduced level compared to the tissue treated with Nys1. Detachment of the tissue base from the keratinocyte layers did not occur under the influence of the antifungal agents.
Based on these results, Nys5 and Nys7 were deemed the most effective antifungals, due to the fact that they considerably inhibited the ability of Candida to colonise and invade the oral epithelium. Novel Nystatin A 1 derivatives reduced LDH activity fourfold compared with the native compound. In the presence of these new polyenes, the extent of LDH activity was comparable to Candida uninfected RHOE tissues, and no significant (P > 0.05) differences in LDH activity were evident for RHOE treated with the different compounds. The LDH activity levels for RHOE treated with the Nystatin A 1 derivatives were significantly lower (P < 0.05) than Candida infected untreated controls and were the same as the uninfected tissue treated only with medium with 1 % (v/v) DMSO (P > 0.05).
Discussion
Since oral candidosis is a commonly encountered opportunistic fungal disease with the potential for dissemination to other organs [26, 27] , effective methods to combat oral candidosis are required. Amongst the limited armoury of drugs for the management of oral fungal infections are the polyene antibiotics that have historically been the most extensively used, largely due to their high antifungal activity and low incidence of fungal resistance [15] . Polyene antifungals are secondary metabolites produced by Streptomyces soil bacteria and consist of a macrolactone ring with a range of conjugated double bonds (3) (4) (5) (6) (7) (8) and several hydroxyl groups. The lactone core is connected by a glycoside bond with an amino sugar moiety, namely mycosamine, and includes a hemiketal fragment with a carboxylic acid group [28] . Both the amino and carboxyl group are two of the most exploited regions in structural modifications of these compounds [20] . The action of polyene antifungals is related to the formation of ion channels in fungal membranes rich in ergosterol; however, interaction, albeit to a lesser extent, also occurs in mammalian membranes containing cholesterol. Within this group, Nystatin A 1 (Fig. 1) is a leading agent in the treatment of oral candidosis and for prophylaxis in patients with a high risk of recurrent infection [10, 11, 15] . Unfortunately, due to toxic side effects after parenteral use, e.g. sclerosing of veins, chills and fever [29] , as well as poor oral distribution associated with low water solubility, Nystatin A 1 may be only administrated in the form of topical preparations. Even then, some formulations such as suspensions or rinses have reduced efficiency because of saliva dilution and a cleaning action of the oral cavity environment. Consequently, the effective drug concentration and a sufficient duration of contact time with the oral mucosa may not be achieved, leading to a therapeutic failure [10] .
In recent years, considerable effort has been made to circumvent the undesirable features of polyene compounds. These studies have involved production of new antibiotic formulations, genetic manipulation of biosynthetic products and chemical modification of natural drugs. Two Nystatin formulations (i.e. liposomal and intralipid) that reduce drug toxicity have been developed [29, 30] . Clinical trials of liposomal Nystatin have been completed [31] , although such products are very expensive for routine antifungal treatment [32] . Meanwhile, the intralipid formulation seems to be a promising, low-cost counterpart; however, this remains in the process of testing [33, 34] .
Genetic engineering methods are based on manipulation of polyene biosynthetic genes in Streptomyces species. During these investigations, several new Nystatin-like polyenes have been developed, with a few characterised with better solubility in water and lower toxicity [35] , e.g. Nystatin A 1 heptaene S44HP, described by Bruheim et al. [36] . Nevertheless, biosynthetic and genetic engineering techniques tend to be time-consuming and, in many cases, result in limited yields of fermentation products [37] . Chemical modification of antibiotic structure appears to be amongst the quickest and most cost effective means to design new improved polyene antifungals. Therefore, a number of polyenes derivatives have been synthesised, and some of them have preferable selective toxicity parameters [38] [39] [40] . However, previous efforts have largely focused on Amphotericin B, a polyene predominantly used in the treatment of systemic mycoses [41] .
Based on the above information, our research has focused on Nystatin A 1 , noting that relatively little had been undertaken to chemically improve this polyene antibiotic. As a result, we present novel Nystatin A 1 derivatives, modified at the amino group, as low toxic and efficient antifungal compounds for use in combating oral candidosis. In this present study, for the first time we describe the effect of these agents in treating in vitro Candida infections of RHOE. Due to the similarity of this tissue model to in vivo conditions, it offers a potential alternative to animal research models [23, 42] in assessing compound performance and generates more comprehensive data than traditional in vitro approaches on the behaviour of novel agents in the oral cavity environment [42, 43] .
Preliminary, investigations showed that despite Nystatin A 1 derivatisation having no apparent increase of antifungal action in vitro, there was a significant reduction in host cell toxicity with the new compounds. To highlight the latter, the semisynthetic derivatives displayed severalfold reduced toxic effects on HaCaT cells (IC50-H 50.82 vs. >300 µg ml ), compared with Nystatin A 1 . These findings indicated that the substitution of Nystatin A 1 at the amino group with a 'bulky' moiety played an essential role for reduction of mammalian cell toxicity. Previously, similar observations were described for Amphotericin B by Borowski and coworkers [44, 45] , who showed that a large substituent at the amino group generated sterical hindrance, which decreased the ability of the antibiotic to form lethal channels in cholesterol containing membranes, whilst still maintaining good affinity for ergosterol rich ones. Our initial results prompted us to undertake this current research further.
It is widely accepted that interaction of Candida with the oral epithelium includes attachment and colonisation, invasion and tissue damage, which are all important stages of infection [8, 9, 46] . In this context, we used a tissue model of Candida infection to examine how the novel compounds influenced these processes and whether they were able to inhibit the development of infection. Due to the poor absorption of polyenes into the tissues [10, 11, 15] and based on cytotoxicity results from the HaCaT cell line, we tested compounds at relatively high concentrations (150 µg ml −1 ). For viability determination of Candida and epithelial tissue cells after RHOE infection, we successfully used a live/ dead assay, allowing differentiation of the viable and dead cell populations of both types (Fig. 2) . The studies revealed that Nystatin A 1 derivatives were highly effective in the in vitro model of oral candidosis. Importantly, these novel compounds induced a high level of Candida cell death compared to untreated Candida infection, with most RHOE cells in the former appearing to be alive. Furthermore, compared with the native drug, we found these derivatives were at least twice as effective as antifungal compounds (Fig 3a) and exhibited significantly lower toxicity to human oral epithelium under infection conditions (Fig. 3b) . These results were in agreement with cytotoxicity studies on HaCaT cells, as we similarly detected Nystatin A 1 to be the most toxic antifungal (Fig. 8) . Nevertheless, there was no statistical difference between the toxicity of these derivatives (P > 0.05; except of Nys8), confirming our assumptions that the type of substituent at the amino group had little impact for toxicity reduction of new derivatives, and it was rather the substitution itself that mattered.
Interestingly, the antifungal efficacy results obtained by live/dead staining contrasted somewhat with the formerly determined MICs from broth microdilution studies, with Nystatin A 1 demonstrating lower activity against Candida than the derivatives in the RHOE model. This effect may be associated with the previously mentioned higher water solubility of the derivatives compared with the native Nystatin. Native Nystatin is a water-insoluble compound [15] due to its high tendency to self-aggregate [19, 44, 47] . Therefore, at high concentrations, water-insoluble aggregates form [19, 47] , and this could decrease its antifungal action. However, predisposition to self-association may be hampered by the presence of a heavy substituent at the amino group of the polyene molecule, and this was previously observed for Amphotericin B derivatives [44] . Therefore, the novel Nystatin A 1 derivatives used here could exhibit reduced aggregation with associated higher water solubility than the parent Nystatin molecule. This in turn could facilitate greater penetration of the derivatives into the biofilm and layers of infected RHOE tissue, thereby enhancing their relative antifungal effects in this model. Overall, despite Nystatin A 1 being the most effective antifungal tested based on the MICs studies, its diffusion might be disrupted through its limited water solubility in the tissue model. In addition, the microtitre plate assay primarily involves testing activity against yeast in planktonic form, whilst the RHOE model largely contains a mixed morphology biofilm (with invading Candida hyphae). It is also conceivable that the derivatives are more effective in combating either the hyphae or the biofilm growth of Candida. However, further work is required to investigate this possibility.
An important caveat to the above is that several limitations of the live/dead staining approach have been reported [48] . Whilst concentrations of the probes and incubation times can optimised, obtaining an equal staining efficiency in complex, multicellular environment may still be difficult to achieve. This is because, the experimental samples usually contain populations of cells at different stages of viability with some cells retaining different dye components at varying levels. As a result, inaccuracies during data analysing may arise.
Additional interesting observations were made in the studies of tissue colonisation and invasion by Candida. Firstly, analysis showed that C. albicans ATCC 10231 extensively colonised the surface of the human oral epithelium and was able to invade the tissue to a high level (Fig. 5a ). Similar to other authors [49, 50] , we showed the presence of Candida biofilm on the RHOE surface, and based on other studies involving clinical isolates of C. albicans [51, 52] , we classified this strain as a 'high invader', with a uniform pattern of invasion (Fig. 9) . Our measurements of the biofilm thickness were likewise consistent with the earlier findings [53] , in which the thickness of Candida biofilm under in vitro conditions was determined at 25-450 µm. Whilst yeast cells were clearly detected within the tissue, hyphae were the predominant fungal elements penetrating all the RHOE layers, and this feature has also previously been noted [51, 52, 54] . Although, yeast forms were characterised to be actively non-invading cells, Jacobsen et al. [55] postulated that hyphae could facilitate the entry of yeast into tissue, and under in vivo conditions, these may contribute to Candida dissemination. As a consequence of Candida-RHOE infection, detachment of the epithelium from the basement membrane was evident, as were the occurrences of vacuolated spaces within the tissue structure, indicating damage. The same symptoms of epithelial disruption were found in the case of C. albicans SC5314 (ATCC MYA-2876) [23, 54] as well as with clinical isolates [51, 56] . Finally, CLSM analysis, supported by the levels of LDH activity, provided a quantitative indicator of tissue damage. The results showed that the Candida were responsible for epithelium destruction after 24 h, with the highest LDH activity occurring in the presence of the fungus without treatment (Fig. 7) .
Importantly, treatment of infected tissues with new polyene compounds successfully inhibited Candida infection (Fig. 5c-e) . Noteworthy was the finding that the Nystatin A 1 derivatives were more effective in combating Candida tissue colonisation than the native Nystatin A 1 , and this was confirmed by live/dead cell calculations. In addition, the presence of novel compounds resulted in thinner, less clustered and disrupted (in the case of Nys1) biofilm-like structures on tissue surfaces, compared to the native antibiotic. We established that the Candida biofilm thickness under the effect of Nys5 and Nys7 derivatives was reduced by 29 % and 36 % respectively, compared with Nystatin A 1 , whereas the compound Nys1 caused a 50 % decrease in fungal biofilm formation, compared with the parent drug (Fig. 6) .
Several authors [49, 50, 57] reported the resistance of in vitro Candida biofilms to antifungals, including Nystatin [58] . Partly in consideration of this, we used relatively high concentrations of compounds (150 µg ml −1 ) and still observed a relatively thick Candida biofilm layer (50 % that of untreated controls) after Nystatin treatment. However, the extent of drug diffusion may also be relevant to these findings [59] . Notwithstanding, novel derivatives exhibited a higher anti-biofilm effect. As mentioned above, this result was most likely associated with improved water solubility of the derivatives. Chandra et al. [53] suggested that resistance of Candida biofilms to antifungals increases during biofilm maturation. It would therefore be interesting to investigate the efficiency of novel compounds on different developmental Candida biofilm phases in the RHOE model, since in the present study we analysed the effect of Nystatin A 1 and its derivatives on the early stages of Candida biofilm formation.
Furthermore, we found that C. albicans was unable to penetrate the oral epithelium after treatment with Nys5 and Nystatin A 1 , whilst moderate and low invasion levels were still seen for tissues after treatment with Nys1 and Nys7. It was particularly interesting to note that the nature of Nystatin modification appeared to influence the extent of C. albicans invasiveness, since complete prevention was found only in the case of Nys5 (N-succinimidyl derivative). We also detected a positive relationship between the MIC (IC50-C) for the derivatives and extent of Candida invasion. Nys1 and Nys7 did not totally prevent Candida invasion of the tissue, and this might correspond with the higher MIC values exhibited by these compounds compared with derivative Nys5, the use of which resulted in an absence of Candida invasion.
Candida colonisation of the epithelium appeared less dependent on derivatisation, although it seemed that Nys1 (N-alkyl derivative) impacted differently on biofilm formation than the others, but this may have been associated with a higher invasion level, since more fungal cells would have penetrated from the surface into the tissue. Nevertheless, the separation of epithelium from the tissue insert membrane was not evident as reported in the absence of polyene compounds. In terms of LDH activity, we demonstrated that Nystatin A 1 was fourfold more toxic to RHOE than its derivatives, with the latter resulting in statistically similar enzyme activity levels to those in the absence of Candida (Fig. 7) .
In conclusion, the present study has examined the action of novel Nystatin A 1 derivatives (modified at the amino group) in an in vitro tissue model infected with C. albicans ATCC 10231. According to our knowledge, no efficiency/ toxicity studies of polyene antibiotics in the Candida-RHOE model have previously been reported. The experiments showed that novel Nystatin derivatives were more effective in terms of antifungal activity than the parent molecule. It is necessary to mention that these derivatives significantly inhibited Candida colonisation, including biofilm-like structure formation and highly reduced or completely prevented Candida invasion. We also showed that these new polyenes were less toxic against keratinocyte cells, as well as the human oral epithelium compared with the natural Nystatin A 1 . Although broth microdilution-derived MICs were not extrapolated to the tissue model, we have proposed a possible explanation for this. We have successfully applied a live/ dead stain to calculate the ratio of live and dead Candida and tissue cells in situ, and these results were comparable with histological observations of RHOE colonisation and invasion by C. albicans and LDH activity measurements. Based on live/dead calculations, we demonstrated that the hierarchy of antifungal activity under tissue conditions was as follows: Nys7 > Nys5 > Nys1 > Nys, and effect on the level of epithelium colonisation and invasion by Candida was: Nys7 ≥ Nys5 > Nys1 > Nys. Meanwhile, toxicity of the polyene antifungals assessed during viability and LDH activity levels decreased as follows: Nys > Nys7 > Nys5 ≥ Nys1.
We therefore report on the benefits of these novel Nystatin A 1 derivatives as alternatives to Nystatin A 1 as the former have greatly reduced toxicity to human epithelial cells with an associated high antifungal activity. Further research into the mechanism of this selective toxicity exhibited by the new Nystatin A 1 derivatives is required, and such studies are currently in progress.
